The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC

Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches. Targeted therapies could serve as effective tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Matthew, Zhang, Wanbin, Yan, Deyue, Kenath, Rajath, Le, Le, Wang, He, Delitto, Daniel, Ostrov, David, Robertson, Keith, Liu, Chen, Pham, Kien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957139/
https://www.ncbi.nlm.nih.gov/pubmed/31929540
http://dx.doi.org/10.1371/journal.pone.0226917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957139/
https://www.ncbi.nlm.nih.gov/pubmed/31929540
http://dx.doi.org/10.1371/journal.pone.0226917

Ejemplares similares